FindTrial
Sign In

Palivizumab

BIOLOGICAL10 trials

Sponsors

Fred Hutchinson Cancer Center, MedImmune LLC, Abbott, AbbVie (prior sponsor, Abbott), Hamad Medical Corporation

Conditions

Bronchopulmonary DysplasiaCancerCongenital Heart DiseaseHealthy Adult ParticipantsPremature BirthRSV InfectionRespiratory Syncytial Virus (RSV)Respiratory Syncytial Virus Infection

Phase 1

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV
CompletedNCT04540627
mAbxience Research S.L.Healthy Adult Participants
Start: 2020-07-06End: 2020-10-23Updated: 2021-10-04

Phase 2

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
CompletedNCT00538785
MedImmune LLCCongenital Heart Disease
Start: 2005-10-31End: 2008-06-30Updated: 2012-02-16
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
CompletedNCT01006629
AbbottBronchopulmonary Dysplasia, Congenital Heart Disease, Premature Birth +1
Start: 2009-11-30End: 2010-07-31Updated: 2011-07-19
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
CompletedNCT03959488
AstraZenecaRespiratory Syncytial Virus Infections
Start: 2019-07-30End: 2023-01-20Updated: 2023-09-21

Phase 3

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
CompletedNCT00014391
Fred Hutchinson Cancer CenterCancer
Start: 1999-02-28End: 2001-10-31Updated: 2010-04-02
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
CompletedNCT00129766
MedImmune LLCRespiratory Syncytial Virus Infections
Start: 2004-11-30End: 2006-05-31Updated: 2013-08-28
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
CompletedNCT01466062
AbbVie (prior sponsor, Abbott)Respiratory Syncytial Virus Infection
Start: 2011-08-31End: 2012-04-30Updated: 2013-06-17
Palivizumab Therapy for RSV-bronchiolitis
CompletedNCT02442427
Hamad Medical CorporationRespiratory Syncytial Virus-bronchiolitis
Start: 2014-09-30End: 2018-02-01Target: 420Updated: 2018-02-27
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
CompletedNCT02968173
AbbVieRespiratory Syncytial Virus (RSV)
Start: 2016-11-09End: 2017-07-13Updated: 2018-03-13
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
CompletedNCT04938830
Merck Sharp & Dohme LLCRSV Infection
Start: 2021-11-30End: 2025-08-01Updated: 2025-10-29

Related Papers

Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials.
2025-06-302 citations
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants
The Journal of Infectious Diseases2024-11-2727 citations
Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150
The Journal of Infectious Diseases2024-11-266 citations
Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials
Pathogens2024-06-1323 citations
1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
Open Forum Infectious Diseases2023-11-272 citations
A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
2012-09-0410 citations